Home > Press > BIND Biosciences, Inc. Awarded NIH Phase I SBIR Contract to Develop Therapeutic Targeted Nanoparticles for Prostate Cancer Therapy
BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company focused on developing therapeutic targeted nanoparticles, announced today that it has been awarded a six month $150,000 Phase I SBIR contract from the National Cancer Institute (NCI) to develop a targeted therapy for hormone refractory prostate cancer (HRPC). Prostate cancer accounts for an estimated 27,000 annual deaths in the U.S. and is an area of enormous unmet medical need.
BIND Biosciences, Inc. Awarded NIH Phase I SBIR Contract to Develop Therapeutic Targeted Nanoparticles for Prostate Cancer Therapy
Cambridge, MA | Posted on October 8th, 2007
"The NCI SBIR funding is one important validation of BIND's therapeutic targeted nanoparticle platform and will accelerate our prostate cancer program," according to Dr. Jeff Hrkach, Vice President of Pharmaceutical Sciences at BIND and the Principal Investigator on this Phase I SBIR program. "By utilizing BIND's targeted polymeric nanoparticle technology, we will be able to develop revolutionary therapies to address prostate cancer."
"BIND was founded, in-part, based on technologies that were developed through a $20M NCI funded Center for Cancer Nanotechnology Excellence. We view this SBIR contract as a continued collaboration with the NCI as we move toward commercializing breakthrough therapies for important human diseases, including cancer," said Glenn Batchelder, President and Chief Executive Officer of BIND. "We are very fortunate to have Dr. Hrkach leading this program with his extensive expertise in polymeric particle drug delivery and his broad drug development experience accumulated during his tenures at Advance Inhalation Research, Alkermes and Momenta."
The NCI SBIR program is a peer-reviewed competitive funding process that provides research support to companies discovering and developing innovative biomedical products for the treatment and diagnosis of cancer. Companies that successfully meet the goals of this Phase I program are eligible to apply for an additional $1,000,000 in Phase II support to continue their development efforts. This work builds on nanoparticle technologies that were originally developed by BIND's scientific founders, Dr. Robert Langer (MIT) and Dr. Omid Farokhzad (Brigham and Women's Hospital - Harvard Medical School) and BIND has licensed the large patent estate covering these technologies on a worldwide exclusive basis.
About BIND Biosciences, Inc.
BIND Biosciences is a privately held biopharmaceutical company focused on developing therapeutic targeted nanoparticles. The company’s product-platform leverages the convergence of polymeric biomaterials, nanoparticle engineering and combinatorial synthesis to uniquely enable BIND to design and optimize targeted nanoparticle therapeutics for specific indications. BIND’s technology concentrates drug at the intended site of action while minimizing systemic exposure, thereby improving efficacy and reducing off-target effects.
The company’s platform is broadly applicable across therapeutic areas with the initial product development efforts focused in cancer and cardiovascular disease. The company anticipates initiating clinical trials for their first product in 2009. Founded in 2006 and backed by leading venture capital firms, Flagship Ventures and Polaris Venture Partners, BIND is based in Cambridge, Massachusetts.
For more information, please click here
BIND Biosciences, Inc.
Glenn Batchelder, President and CEO, 617-491-3400
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
New research could lead to more efficient electrical energy storage March 4th, 2015
Energy-generating cloth could replace batteries in wearable devices March 4th, 2015
The taming of magnetic vortices: Unified theory for skyrmion-materials March 3rd, 2015
Black phosphorus is new 'wonder material' for improving optical communication March 3rd, 2015
Patent for the Novel Cancer Therapies – Ceramide Nanoliposomes March 4th, 2015
Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015
Democratizing synthetic biology: New method makes research cheaper, faster, and more accessible March 3rd, 2015
Pens filled with high-tech inks for do-it-yourself sensors March 3rd, 2015
MIG Takes a Roll-Up-Your-Sleeves Approach with Revamped MEMS/Sensors Technical Event -- MIG welcomes technologists to MEMS Technical Congress, emphasizes working groups and breakout sessions on emerging MEMS & sensors, tech transfer and integration March 6th, 2015
Phenom-World announces the Phenom XL, world’s fastest desktop SEM to handle large samples March 6th, 2015
Air Bearing Stage / Systems Introduced by PI at Photonics West March 6th, 2015
Get ready for NanoDays! March 5th, 2015
Anousheh Ansari Wins the National Space Society's Space Pioneer Award for "Service to the Space Community" March 5th, 2015
Enhanced Graphene Components for Next Generation Racing Yacht March 5th, 2015
Rice's Stephan Link honored for nanoscience research: The Welch Foundation honors ‘rising star’ with $100,000 Hackerman Award February 26th, 2015
Cutting-edge technology optimizes cancer therapy with nanomedicine drug combinations: UCLA bioengineers develop platform that offers personalized approach to treatment February 24th, 2015